Layman Melissa 4
4 · Flexion Therapeutics Inc · Filed Mar 3, 2021
Insider Transaction Report
Form 4
Layman Melissa
Chief Commercial Officer
Transactions
- Award
Common Stock
2021-03-01+20,100→ 108,476 total - Award
Performance Restricted Stock Unit Award
2021-03-01+30,150→ 30,150 totalExercise: $0.00→ Common Stock (30,150 underlying)
Footnotes (3)
- [F1]Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan.
- [F2]Represents the maximum number of shares deliverable under the performance restricted stock unit award.
- [F3]Upon confirmation by the Board of Directors or the Compensation Committee thereof that a specified amount of 2021 revenues from ZILRETTA product sales is achieved, 25% of the shares eligible for vesting under the restricted stock unit award shall vest in 2022 upon confirmation of such revenues being achieved and thereafter on January 1 of the subsequent three years so that all of such shares will have vested on January 1, 2025.